Cargando…

2802. Occupational Exposure to the Ugandan Strain of Zika Virus in a Laboratory Worker in the United States: Clinical Presentation, Viral Persistence, and Antibody Response

BACKGROUND: A laboratory worker suffered an accidental needle stick resulting in infection with the Ugandan strain (MR766) of Zika virus (ZIKV), a strain that has rarely been studied in humans. We report the clinical presentation and outcomes, molecular and serological diagnostic results, and immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Lichtenberger, Paola, Ricciardi, Mike, Solorzano, Dalhila, Raccamarich, Patricia, Leda, Ana R, Sharkey, Mark, Walkins, David, Mulligan, Mark, Doblecki-Lewis, Susanne, Stevenson, Mario, Alcaide, Maria L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810082/
http://dx.doi.org/10.1093/ofid/ofz360.2479
_version_ 1783462160437870592
author Lichtenberger, Paola
Ricciardi, Mike
Solorzano, Dalhila
Raccamarich, Patricia
Leda, Ana R
Sharkey, Mark
Walkins, David
Mulligan, Mark
Doblecki-Lewis, Susanne
Stevenson, Mario
Alcaide, Maria L
author_facet Lichtenberger, Paola
Ricciardi, Mike
Solorzano, Dalhila
Raccamarich, Patricia
Leda, Ana R
Sharkey, Mark
Walkins, David
Mulligan, Mark
Doblecki-Lewis, Susanne
Stevenson, Mario
Alcaide, Maria L
author_sort Lichtenberger, Paola
collection PubMed
description BACKGROUND: A laboratory worker suffered an accidental needle stick resulting in infection with the Ugandan strain (MR766) of Zika virus (ZIKV), a strain that has rarely been studied in humans. We report the clinical presentation and outcomes, molecular and serological diagnostic results, and immunological response. A 34-year-old Brazilian-born female laboratory researcher, presented with malaise, skin rash, myalgia and joint pain 10 days after an accidental needle stick while inoculating a mouse with ZIKV-MR766. On physical examination she had bilateral maculopapular rash on the cheeks, and tender effusions at the metacarpal and proximal interphalangeal joints and ankles. Symptoms and signs resolved within 3 weeks. ZIKV infection was confirmed by Nucleic Acid Amplification Test (Lab Corp®) in urine. Serological testing using the ZIKV IgM ELISA test from Lab Corp®, and a confirmatory plaque reduction neutralization test (PRNT) in accordance with the Centers for Disease Control and Prevention (CDC), results were negative. METHODS: Whole blood, plasma, urine, saliva, and a vaginal swab were collected from day (D) 14 post exposure (PE) to D104 PE. A novel, antibody competition-based ZIKV diagnostic test (highly specific for ZIKV antibodies) was performed in serum, and detection of ZIKV-MR766 genomic RNA was performed in all body fluids longitudinally. RESULTS: Antibody response revealed broad IgM response to both ZIKV-Paraiba (strain from the 2015 outbreak) and ZIKV-MR766 during the acute phase of the infection, suggesting cross-reactivity. There was no cross-reactivity against dengue or yellow fever viruses. An IgG response was detected against both ZIKV strains and increased until D104 PE. ZIKV RNA was detected in whole blood, saliva, urine, and the vaginal swab at D14 PE. At D20 PE, virus was only detectable in whole blood at a value of less than 37 copies per mL. At D23 PE, there was no detectable virus. (figure). CONCLUSION: This case highlights the potential for ZIKV occupational exposure. Findings may be useful for the development of diagnostic tests against ZIKV as we were able to accurately determine time of exposure, presence of virus in body fluids, development of symptoms, and antibody responses after a well-documented infection. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810082
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68100822019-10-28 2802. Occupational Exposure to the Ugandan Strain of Zika Virus in a Laboratory Worker in the United States: Clinical Presentation, Viral Persistence, and Antibody Response Lichtenberger, Paola Ricciardi, Mike Solorzano, Dalhila Raccamarich, Patricia Leda, Ana R Sharkey, Mark Walkins, David Mulligan, Mark Doblecki-Lewis, Susanne Stevenson, Mario Alcaide, Maria L Open Forum Infect Dis Abstracts BACKGROUND: A laboratory worker suffered an accidental needle stick resulting in infection with the Ugandan strain (MR766) of Zika virus (ZIKV), a strain that has rarely been studied in humans. We report the clinical presentation and outcomes, molecular and serological diagnostic results, and immunological response. A 34-year-old Brazilian-born female laboratory researcher, presented with malaise, skin rash, myalgia and joint pain 10 days after an accidental needle stick while inoculating a mouse with ZIKV-MR766. On physical examination she had bilateral maculopapular rash on the cheeks, and tender effusions at the metacarpal and proximal interphalangeal joints and ankles. Symptoms and signs resolved within 3 weeks. ZIKV infection was confirmed by Nucleic Acid Amplification Test (Lab Corp®) in urine. Serological testing using the ZIKV IgM ELISA test from Lab Corp®, and a confirmatory plaque reduction neutralization test (PRNT) in accordance with the Centers for Disease Control and Prevention (CDC), results were negative. METHODS: Whole blood, plasma, urine, saliva, and a vaginal swab were collected from day (D) 14 post exposure (PE) to D104 PE. A novel, antibody competition-based ZIKV diagnostic test (highly specific for ZIKV antibodies) was performed in serum, and detection of ZIKV-MR766 genomic RNA was performed in all body fluids longitudinally. RESULTS: Antibody response revealed broad IgM response to both ZIKV-Paraiba (strain from the 2015 outbreak) and ZIKV-MR766 during the acute phase of the infection, suggesting cross-reactivity. There was no cross-reactivity against dengue or yellow fever viruses. An IgG response was detected against both ZIKV strains and increased until D104 PE. ZIKV RNA was detected in whole blood, saliva, urine, and the vaginal swab at D14 PE. At D20 PE, virus was only detectable in whole blood at a value of less than 37 copies per mL. At D23 PE, there was no detectable virus. (figure). CONCLUSION: This case highlights the potential for ZIKV occupational exposure. Findings may be useful for the development of diagnostic tests against ZIKV as we were able to accurately determine time of exposure, presence of virus in body fluids, development of symptoms, and antibody responses after a well-documented infection. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810082/ http://dx.doi.org/10.1093/ofid/ofz360.2479 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Lichtenberger, Paola
Ricciardi, Mike
Solorzano, Dalhila
Raccamarich, Patricia
Leda, Ana R
Sharkey, Mark
Walkins, David
Mulligan, Mark
Doblecki-Lewis, Susanne
Stevenson, Mario
Alcaide, Maria L
2802. Occupational Exposure to the Ugandan Strain of Zika Virus in a Laboratory Worker in the United States: Clinical Presentation, Viral Persistence, and Antibody Response
title 2802. Occupational Exposure to the Ugandan Strain of Zika Virus in a Laboratory Worker in the United States: Clinical Presentation, Viral Persistence, and Antibody Response
title_full 2802. Occupational Exposure to the Ugandan Strain of Zika Virus in a Laboratory Worker in the United States: Clinical Presentation, Viral Persistence, and Antibody Response
title_fullStr 2802. Occupational Exposure to the Ugandan Strain of Zika Virus in a Laboratory Worker in the United States: Clinical Presentation, Viral Persistence, and Antibody Response
title_full_unstemmed 2802. Occupational Exposure to the Ugandan Strain of Zika Virus in a Laboratory Worker in the United States: Clinical Presentation, Viral Persistence, and Antibody Response
title_short 2802. Occupational Exposure to the Ugandan Strain of Zika Virus in a Laboratory Worker in the United States: Clinical Presentation, Viral Persistence, and Antibody Response
title_sort 2802. occupational exposure to the ugandan strain of zika virus in a laboratory worker in the united states: clinical presentation, viral persistence, and antibody response
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810082/
http://dx.doi.org/10.1093/ofid/ofz360.2479
work_keys_str_mv AT lichtenbergerpaola 2802occupationalexposuretotheugandanstrainofzikavirusinalaboratoryworkerintheunitedstatesclinicalpresentationviralpersistenceandantibodyresponse
AT ricciardimike 2802occupationalexposuretotheugandanstrainofzikavirusinalaboratoryworkerintheunitedstatesclinicalpresentationviralpersistenceandantibodyresponse
AT solorzanodalhila 2802occupationalexposuretotheugandanstrainofzikavirusinalaboratoryworkerintheunitedstatesclinicalpresentationviralpersistenceandantibodyresponse
AT raccamarichpatricia 2802occupationalexposuretotheugandanstrainofzikavirusinalaboratoryworkerintheunitedstatesclinicalpresentationviralpersistenceandantibodyresponse
AT ledaanar 2802occupationalexposuretotheugandanstrainofzikavirusinalaboratoryworkerintheunitedstatesclinicalpresentationviralpersistenceandantibodyresponse
AT sharkeymark 2802occupationalexposuretotheugandanstrainofzikavirusinalaboratoryworkerintheunitedstatesclinicalpresentationviralpersistenceandantibodyresponse
AT walkinsdavid 2802occupationalexposuretotheugandanstrainofzikavirusinalaboratoryworkerintheunitedstatesclinicalpresentationviralpersistenceandantibodyresponse
AT mulliganmark 2802occupationalexposuretotheugandanstrainofzikavirusinalaboratoryworkerintheunitedstatesclinicalpresentationviralpersistenceandantibodyresponse
AT dobleckilewissusanne 2802occupationalexposuretotheugandanstrainofzikavirusinalaboratoryworkerintheunitedstatesclinicalpresentationviralpersistenceandantibodyresponse
AT stevensonmario 2802occupationalexposuretotheugandanstrainofzikavirusinalaboratoryworkerintheunitedstatesclinicalpresentationviralpersistenceandantibodyresponse
AT alcaidemarial 2802occupationalexposuretotheugandanstrainofzikavirusinalaboratoryworkerintheunitedstatesclinicalpresentationviralpersistenceandantibodyresponse